The future of oncology treatment through diagnostic testing.
作者信息
Oakley Gerard
机构信息
Joan C. Edwards School of Medicine, Marshall University, USA.
出版信息
MLO Med Lab Obs. 2013 Dec;45(12):38.
PMID:24409595
Abstract
摘要
相似文献
1
The future of oncology treatment through diagnostic testing.通过诊断检测实现肿瘤治疗的未来。
MLO Med Lab Obs. 2013 Dec;45(12):38.
2
[Diagnostic and predictive analyses of cytological specimens of non-small cell lung cancer: strategies and challenges].[非小细胞肺癌细胞学标本的诊断与预测分析：策略与挑战]
Pneumologie. 2013 Apr;67(4):198-204. doi: 10.1055/s-0032-1326344. Epub 2013 Apr 10.
3
Personalized therapy for non-small cell lung cancer: hype or clinical reality?非小细胞肺癌的个性化治疗：炒作还是临床现实？
Semin Thorac Cardiovasc Surg. 2011 Spring;23(1):30-5. doi: 10.1053/j.semtcvs.2011.03.007.
4
First-line therapy of mutated non-small cell lung cancer: an update.突变型非小细胞肺癌的一线治疗：最新进展
Onkologie. 2012;35(5):293-9. doi: 10.1159/000338529. Epub 2012 Apr 24.
5
Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.非小细胞肺癌的分子检测周转时间：监测一个动态目标
Clin Lung Cancer. 2018 Sep;19(5):e589-e590. doi: 10.1016/j.cllc.2018.04.005. Epub 2018 May 4.
6
The tissue is the issue: personalized medicine for non-small cell lung cancer.组织是关键：非小细胞肺癌的个体化医疗。
Clin Cancer Res. 2010 Oct 15;16(20):4909-11. doi: 10.1158/1078-0432.CCR-10-2005. Epub 2010 Oct 5.
7
Biomarker testing in non-small cell lung cancer: a clinician's perspective.非小细胞肺癌中的生物标志物检测：临床医生视角
Arch Pathol Lab Med. 2015 Apr;139(4):448-50. doi: 10.5858/arpa.2014-0085-ED. Epub 2014 Aug 28.
8
[Molecular targeted therapies and cytotoxics: Friends or foes?].[分子靶向疗法与细胞毒性药物：是友还是敌？]
Bull Cancer. 2015 Jun;102(6 Suppl 1):S91-2. doi: 10.1016/S0007-4551(15)31223-6.
9
Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC).非小细胞肺癌（NSCLC）分子检测的报销情况
Am J Manag Care. 2018 Feb;24(2 Spec No.):SP37-SP42.
10
"Personalizing" therapy for non-small cell lung cancer.为非小细胞肺癌“个体化”治疗。
Semin Thorac Cardiovasc Surg. 2010 Summer;22(2):118-20. doi: 10.1053/j.semtcvs.2010.08.005.
Zotero 插件